Skip to main content

Selected peptides as drug candidates directed to pain and neurodegeneration

Objective

"BLV200703/4 is a small molecule discovered jointly by groups from the University of Lisbon (Portugal) and Girona (Spain) that proved its efficacy in analgesia from behavioural tests in rats. The same molecule was tested in a platform that screens potential pharmacological molecules/compounds for neurodegenerative diseases with positive results. The platform is owned by Bioalvo, SA (Portugal). The preliminary results so far obtained regarding efficacy and toxicology of the molecule are encouraging and the academic inventors and the industrial developers are committed to take it into preclinical tests. However, a previous phase of lead optimisation is needed where a well devised strategy will make use of medicinal chemistry methodologies combined with robust in vitro and in vivo assays, in order to achieve the best pharmacological and ADME/toxicity characteristics for our lead molecule. This requires technology, knowledge and innovation transfer since the inventors and Bioalvo are unable to perform this endeavour on their own. Synovo, a German company expert in ADME/tox tests and the University of Tuebingen, with a group expert in Medicinal Chemistry, joined Bioalvo and the Universities of Lisbon and Girona to transfer all knowledge, technology and innovation necessary to make possible that BLV200703 or one of its future derivatives reaches pre-clinical stage. This project fits the ""Developability Assessment Logic Plan"" of BLV200703 as established with a consulting company expert in drug development. Not only all the participants are committed to the success of this product development, they are also committed to two-ways exchange of information and technology that strength their activity in the future. For instance, in the end of this project Bioalvo SA will have a MedChem unit that will strength future development of new products and the Universities of Lisbon and Girona will be able to carry out basic early toxicology tests as part of their research."

Call for proposal

FP7-PEOPLE-IAPP-2008
See other projects for this call

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Address
Avenida Prof Egas Moniz
1649 028 Lisboa
Portugal
Activity type
Research Organisations
EU contribution
€ 248 037
Administrative Contact
Miguel Castanho (Prof.)

Participants (4)

BIOALVO S.A.
Portugal
EU contribution
€ 84 942
Address
Edifício Icat, Campus Da Fcul, Campo Grande
1749-016 Lisbon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patricia Calado (Dr.)
UNIVERSITAT DE GIRONA
Spain
EU contribution
€ 107 603
Address
Placa Sant Domenec 3
17004 Girona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bardaji Eduard (Dr.)
SYNOVO GMBH
Germany
EU contribution
€ 123 876
Address
Paul Ehrlich Str 15
72076 Tuebingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Burnet (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 95 437
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Stefan Laufer (Prof.)